$ACET:NASDAQ · Adicet Bio, Inc.
Conviction from: NASDAQ
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.
More about this company
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Not currently held by tracked 13F filers — this page aggregates activist, insider, politician and research activity.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-04-10 | SCHEDULE 13D/A | ORBIMED ADVISORS LLC | 8.8% | Med | filing |
| Filed | Insider | Role | Shares | Value | |
|---|
| 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. | 10%-owner | 223,596 | $1,603,934 | Form 4 |